Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, all. Damian here with a glimpse at…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, all. Damian here with a glimpse at the next big thing in Alzheimer’s disease, Pfizer’s future in treating obesity, and the downstream effects of a biotech slump.
What's Your Reaction?
